UK regulator authorises Pfizer-BioNTech shot for JN.1 COVID variant-February 2024-www.financetom.com

UK regulator authorises Pfizer-BioNTech shot for JN.1 COVID variant

News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities

UK regulator authorises Pfizer-BioNTech shot for JN.1 COVID variant

Jul 24, 2024 9:27 AM

July 24 (Reuters) - Britain's health regulator said on

Wednesday it has authorised Pfizer ( PFE ) and BioNTech's

updated COVID-19 vaccine that targets the JN.1

subvariant of the coronavirus for use in infants, children and

adults.

Previous page： Applied Industrial Fiscal Q1 Earnings, Sales Rise; Annual EPS Outlook Upgraded Next page： MSCI's Q3 profit beats on record asset-based fee run rate

Comments

Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.

Show More Comments

Related Articles >

Applied Industrial Fiscal Q1 Earnings, Sales Rise; Annual EPS Outlook Upgraded

Oct 28, 2025

06:58 AM EDT, 10/28/2025 (MT Newswires) -- Applied Industrial Technologies ( AIT ) reported fiscal Q1 earnings Tuesday of $2.63 per diluted share, up from $2.36 a year earlier. Analysts surveyed by FactSet expected $2.49. Net sales for the quarter ended Sept. 30 were $1.2 billion, up from $1.1 billion a year earlier. Analysts polled by FactSet expected $1.19 billion....

MSCI's Q3 profit beats on record asset-based fee run rate

Oct 28, 2025

Overview * MSCI ( MSCI ) Q3 revenue grows 9.5% but misses analyst expectations * Adjusted EPS for Q3 beats consensus, reflecting strong operational performance * Company announces new $3 bln share repurchase program, indicating confidence in future growth Outlook * MSCI ( MSCI ) raises full-year 2025 operating expense guidance to $1,415-$1,445 mln * Financial analytics firm expects full-year...

Novartis Maintains Outlook Even As Generics Bite Into Profits

Oct 28, 2025

Swiss pharmaceutical major Novartis AG ( NVS ) reported third-quarter 2025 results on Tuesday, reaffirming its full-year guidance as strong sales from key growth drugs offset mounting generic competition in the U.S. The company’s net sales rose 8% year over year to $13.91 billion, missing Wall Street’s consensus estimate of $14.11 billion. On a constant-currency (cc) basis, sales were up...

Prospect Capital Corporation Announces Pricing of $167 Million 5.5% Oversubscribed Institutional Unsecured Notes Offering

Oct 28, 2025

NEW YORK, Oct. 28, 2025 (GLOBE NEWSWIRE) -- Prospect Capital Corporation ( PSEC ) (“Prospect”, “our”, or “we”) announced today that Prospect priced an institutional offering of approximately $167 million in aggregate principal amount of 5.5% Series A Notes due 2030 (the “Notes”) on October 27, 2025. “We appreciate the strong support and interest we received from over 40 institutional...